Teva Pharmaceutical Industries (TEVA) Net Margin (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly Net Margin of 9.29% for Q1 2026, up 364.0% year-on-year from 2.0% in Q1 2025, and down 6.86% on a QoQ basis from 9.98% in Q4 2025.
Teva Pharmaceutical Industries (TEVA) Net Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Net Margin for 18 consecutive years, with 9.29% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 364.0% year-over-year to 9.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.95% (up 1761.0% YoY) and the FY2025 annual result came in at 8.13%, up 1998.0% from the prior year.
- Net Margin declined to 9.29% in Q1 2026 per TEVA's latest filing, from 9.98% in the prior quarter.
- Over the last five years, Net Margin for TEVA reached as high as 13.59% in Q1 2024 and fell as low as 40.3% in Q4 2023.
- A 5-year average of 7.05% and a median of 6.91% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin slumped 3066 bps — and 2024, when it soared 3081 bps.
- Year by year, Net Margin stood at 34.35% in 2022, then slipped by 17 bps to 40.3% in 2023, then surged by 76 bps to 9.48% in 2024, then soared by 205 bps to 9.98% in 2025, then fell by 7 bps to 9.29% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 9.29%, 9.98%, and 9.64% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.29% |
| Dec 31, 2025 | 9.98% |
| Sep 30, 2025 | 9.64% |
| Jun 30, 2025 | 6.73% |
| Mar 31, 2025 | 5.65% |
| Dec 31, 2024 | -9.48% |
| Sep 30, 2024 | -9.07% |
| Jun 30, 2024 | -21.04% |
| Mar 31, 2024 | 13.59% |
| Dec 31, 2023 | -40.30% |
| Sep 30, 2023 | 1.97% |
| Jun 30, 2023 | -23.39% |
| Mar 31, 2023 | -6.91% |
| Dec 31, 2022 | -34.35% |
| Sep 30, 2022 | 1.78% |
| Jun 30, 2022 | -7.34% |
| Mar 31, 2022 | -26.58% |
| Dec 31, 2021 | -3.68% |
| Sep 30, 2021 | 7.87% |
| Jun 30, 2021 | 5.37% |